Home / Research library / Agomelatine Powder
Agomelatine Powder: molecular data, studies & sources
Agomelatine Powder is catalogued here as a research compound. This profile brings together the molecular source record, selected indexed publications and available supplier comparisons. Evidence for a named substance does not authenticate a commercial product.
Compiled by PeptideTech Editors · Sources checked · Selected bibliography, not a systematic review
Molecular formula, weight & structure
- Molecular formula (MF)
- C15H17NO2
- Molecular weight (MW)
- 243.30 g/mol
- PubChem compound ID
- 82148
- Record title
- Agomelatine
Values describe the selected PubChem molecular entity. Counterions, salt forms, hydration and sequence changes can alter the supplied material. Confirm the exact identity against the supplier specification.
Source: PubChem CID 82148 · retrieved 2026-09-21
Chemical identifiers and source data
- IUPAC name
- N-[2-(7-methoxynaphthalen-1-yl)ethyl]acetamide
- InChIKey
- YJYPHIXNFHFHND-UHFFFAOYSA-N
- SMILES
- CC(=O)NCCC1=CC=CC2=C1C=C(C=C2)OC
Identifiers
- PubChem CID
- 82148
- CAS Registry Number
- 138112-76-2via ChemIDplus, EPA DSSTox, FDA GSRS
- FDA UNII
- 137R1N49AD
- ChEMBL ID
- CHEMBL10878
- InChIKey
- YJYPHIXNFHFHND-UHFFFAOYSA-N
- Wikidata
- Q395229
Other names and development codes: S-20098
CAS numbers are published only from ChemIDplus, EPA DSSTox or the FDA Global Substance Registration System; UNII codes are confirmed in FDA GSRS by structure, sequence or exact name. Checked 2026-10-07.
Calculated molecular descriptors
| Monoisotopic (exact) mass | 243.1259 Da |
|---|---|
| Heavy atoms | 18 |
| Hydrogen-bond donors | 1 |
| Hydrogen-bond acceptors | 2 |
| Rotatable bonds | 4 |
| Topological polar surface area | 38.3 Ų |
| Calculated logP (Crippen) | 2.53 |
| Rings | 2 |
| Stereocenters | 0 |
| Formal charge | 0 |
Computed with RDKit from the published SMILES (Crippen logP, topological polar surface area). Calculated descriptors are not measured properties of a supplied batch.
US regulatory status & drug development
Drug development record (ChEMBL)
Harmonized drug-development record from ChEMBL. The highest clinical stage is the furthest stage reached, as recorded by ChEMBL; it can lag regulatory approvals, and it is not an approval of a research-supplier product.
- ChEMBL ID
- CHEMBL10878
- Modality
- Small molecule
- Highest clinical stage
- Approved in at least one jurisdiction (ChEMBL phase 4)
- Record name
- AGOMELATINE
Mechanism of action
- Melatonin receptor agonist · target: Melatonin receptor (MTNR1A)
- Serotonin 2c (5-HT2c) receptor antagonist · target: 5-hydroxytryptamine receptor 2C (HTR2C)
Synonyms, codes and trade names
- Synonyms and development codes
- Agomelatine · S-20098 · S20098
Identity check: Identical standard InChIKey to the PubChem record. Source: ChEMBL CHEMBL10878 (EMBL-EBI, CC BY-SA 3.0) · retrieved 2026-10-07
Registered clinical trials
Studies registered on ClinicalTrials.gov that list Agomelatine as an intervention. Studies that only measure the molecule as a biomarker, or use it only as a comparator or background arm for another drug, are excluded. A registration describes a planned or completed protocol; it does not report a result. Active studies are listed first.
19 registered studies matched, 1 currently active or recruiting, 1 with results posted on ClinicalTrials.gov.
- By highest phase
- Phase 4 · 8Phase 3 · 7Phase 2 · 1Not applicable · 3
- By registry status
- Completed · 13Unknown · 4Not Yet Recruiting · 1Withdrawn · 1
| Study | Phase · status | Conditions | Sponsor · size |
|---|---|---|---|
| Switching Medication and Augmentation Strategies for SSRI-Resistant Adolescent Depression（SMART-I)NCT07011693 · start 2025-06-20 · primary completion 2027-06 | Phase 4Not Yet Recruiting | Major Depressive Disorder (MDD) | Xinyu Zhou400 participants |
| A Study on the Efficacy of Agomelatine Combined With Antipsychotics to Treat Negative Symptoms in SchizophreniaNCT05646264 · start 2023-01-01 · primary completion 2023-08-01 | Phase 4Unknown | Schizophrenia · Negative Symptoms in Schizophrenia | Shanghai Mental Health Center220 participants |
| Prophylactic Effects of Agomelatine for Poststroke DepressionNCT05426304 · start 2022-10-01 · primary completion 2024-05-31 | Phase 4Unknown | Depression · Acute Ischemic Stroke | First Affiliated Hospital, Sun Yat-Sen University420 participants |
| A Double-blind, Placebo-controlled Study of Antidepressant Augmentation With AgomelatineNCT04589143 · start 2020-10-01 · primary completion 2022-12-30 | Phase 4Completed | Major Depressive Disorder | Central South University137 participants |
| the Efficacy and Safety of Agomelatine in the Patients With Parkinson's DiseaseNCT03977441 · start 2019-07 · primary completion 2020-12 | Phase 4Unknown | Parkinson Disease · Depression · Sleep Disorders · Circadian Rhythm Disorders | Second Affiliated Hospital of Soochow University240 participants |
| Melatonin Decreases Eye Pressure in Normotensive PatientsNCT03193112 · start 2017-06-16 · primary completion 2017-10-15 | Not applicableCompleted | Depressive Disorder | Kahramanmaras Sutcu Imam University20 participants |
| Comparison of the Efficacy, Safety, and Relapse of ECT to ECT Plus Agomelatine for Depressed PatientsNCT04181567 · start 2014-03-03 · primary completion 2019-10-08 | Phase 4Completed | Major Depressive Disorder | Kaohsiung Kai-Suan Psychiatric Hospital97 participants |
| Cardiovascular Effects of Agomelatine and Escitalopram in Patients With Major Depressive Disorder (MDD)NCT01483053 · start 2014-01 · primary completion 2015-02 | Phase 4Unknown | Major Depressive Disorder (MDD) | Baker Heart and Diabetes Institute40 participants |
| Agomelatine Treatment of Depression in Schizophrenia (AGOPSYCH)NCT01822418 · start 2013-01 · primary completion 2015-12 | Phase 4Completed | Schizophrenia · Schizoaffective Disorder · Delusional Disorder | Central Institute of Mental Health, Mannheim27 participants |
| A Study of Vortioxetine (Lu AA21004) in Comparison to Agomelatine in Adults Suffering From Major Depression With Inadequate Response to Previous MedicationNCT01488071 · start 2012-01 · primary completion 2012-12 | Phase 3CompletedResults posted 2014-03-26 | Major Depressive Disorder | H. Lundbeck A/S495 participants |
Show 9 more registered studies
| Study | Phase · status | Conditions | Sponsor · size |
|---|---|---|---|
| Agomelatine in Depressed Patients With FibromyalgiaNCT01731899 · start 2010-06 · primary completion 2012-10 | Not applicableCompleted | Major Depression · Fibromyalgia | Universidad de Granada27 participants |
| Efficacy of Agomelatine in Patients With Obsessive-Compulsive DisorderNCT01108393 · start 2010-05 · primary completion 2012-08 | Phase 2Completed | Obsessive Compulsive Disorder | Institut de Recherches Internationales Servier74 participants |
| Efficacy, Safety and Tolerability of Agomelatine Sublingual Tablets in the Treatment of Major Depressive DisorderNCT01110889 · start 2010-05 · primary completion 2011-07 | Phase 3Completed | Major Depressive Disorder | Novartis Pharmaceuticals582 participants |
| Efficacy, Safety and Tolerability of Agomelatine Sublingual Tablets in the Treatment of Major Depressive Disorder (MDD)NCT01110902 · start 2010-05 · primary completion 2011-06 | Phase 3Completed | Major Depressive Disorder | Novartis Pharmaceuticals589 participants |
| Efficacy, Safety and Tolerability of Agomelatine in the Prevention of Relapse of Major Depressive DisorderNCT00467402 · start 2007-04 · primary completion 2009-09 | Phase 3Completed | Major Depressive Disorder | Novartis644 participants |
| A Placebo- and Paroxetine-controlled Study of the Efficacy, Safety and Tolerability of Agomelatine (25 or 50 mg) in the Treatment of Major Depressive Disorder (MDD)NCT00463242 · start 2007-03 · primary completion 2008-06 | Phase 3Completed | Major Depressive Disorder | Novartis501 participants |
| Efficacy, Safety and Tolerability of Agomelatine in the Treatment of Major Depressive DisorderNCT00411099 · start 2006-12 · primary completion 2008-01 | Phase 3Completed | Major Depressive Disorder | Novartis508 participants |
| Efficacy, Safety and Tolerability of Agomelatine in the Treatment of Major Depressive DisorderNCT00411242 · start 2006-12 · primary completion 2008-01 | Phase 3Completed | Major Depressive Disorder (MDD) | Novartis503 participants |
| The Effect of Agomelatine or Fluoxentine on Heart Rate Variability in Patients With Major Depressive DisorderNCT00451490 · start 2006-10 | Not applicableWithdrawnWhy stopped: This study not get the approval by the drug company | Depressive Disorder, Major | National Taiwan University Hospital24 participants |
Registry check 2026-10-09 · Run this search on ClinicalTrials.gov
Human intervention studies
Selected studies in which participants received Agomelatine, with their indexed or reviewed study type. Check the original article for the formulation, population and controls. Studies that only measured the molecule, or used it as a comparator, are listed separately below and are not counted as intervention studies.
- Human study · PubMed trial index Compound given to participants
Efficacy and Safety of Electroacupuncture Combined with Agomelatine Tablets Therapy in Treating Insomnia After Stroke.
Han R, Wei W · Journal of molecular neuroscience : MN · 2025
PMID 40782216 · DOI: 10.1007/s12031-025-02394-9
- Human study · PubMed trial index Compound given to participants
Agomelatine but not melatonin improves fatigue perception: a longitudinal proof-of-concept study.
Pardini M, Cordano C, Benassi F et al. · European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology · 2014
PMID 24636462 · DOI: 10.1016/j.euroneuro.2014.02.010
- Human study · PubMed trial index Compound given to participants
Agomelatine might be more appropriate for elderly, depressed, type 2 diabetes mellitus patients than paroxetine/fluoxetine.
Liang Z, Jia Y, Zhao L et al. · Aging · 2021
PMID 34610580 · DOI: 10.18632/aging.203586
- Human study · PubMed trial index Compound given to participants
Antidepressant effect in older depressed patients: the lessons of two agomelatine trials.
Goodwin GM, Thomas P, Heun R et al. · International clinical psychopharmacology · 2017
PMID 28383308 · DOI: 10.1097/YIC.0000000000000174
- Human study · PubMed trial index Compound given to participants
Agomelatine Increases BDNF Serum Levels in Depressed Patients in Correlation with the Improvement of Depressive Symptoms.
Martinotti G, Pettorruso M, De Berardis D et al. · The international journal of neuropsychopharmacology · 2016
PMID 26775293 · DOI: 10.1093/ijnp/pyw003
Preclinical research, reviews & other publications
Animal studies, laboratory experiments, reviews and other indexed papers answer different questions. A review is secondary evidence; a case report does not estimate how often an outcome occurs.
- Review · secondary evidence
[Agomelatine].
Tessmer M · Medizinische Monatsschrift fur Pharmazeuten · 2009
PMID 19777735
- Review · secondary evidence
Agomelatine in depression.
Smeraldi E, Delmonte D · Expert opinion on drug safety · 2013
PMID 24033095 · DOI: 10.1517/14740338.2013.828690
- Review · secondary evidence
Focus on agomelatine.
Green B · Current medical research and opinion · 2011
PMID 21271795 · DOI: 10.1185/03007995.2011.554534
Agomelatine Powder supplier sources
Scientific sources describe molecules and experiments. The commercial links below identify recorded supplier packages. A publication or chemical database entry does not verify the seller, purity, sterility or contents of a lot. Some links are affiliate links; see our disclosure.
Agomelatine Powder for sale: compare prices, sizes and forms from every tracked supplier →
| Supplier | Recorded packages | Example source listing |
|---|---|---|
| Amino USAUSD | 1000mg Powder1 recorded offers | 1000mg Powder · $40.00Checked Nov 6, 2026Supplier listing, Agomelatine Powder 1000mg Powder, Amino USA, opens in a new tab |
Reference sources & further reading
- PubChem compound record 82148 — chemical identity and structure.
- ChEMBL drug record CHEMBL10878 — development stage, mechanism and synonyms.
- FDA Global Substance Registration System: UNII 137R1N49AD — substance identity, names and codes.
- Wikipedia: Agomelatine — Background encyclopedia; not a primary clinical source.
The citations above link directly to publication records. Encyclopedia links are background reading and are not used to establish clinical effectiveness.
Search for additional research
These links run searches; their results have not been individually reviewed and can include unrelated compounds.
Research information is not a dosing guide or a recommendation for personal use. Study findings are specific to the formulation, population and methods tested. Read our source and correction policy.
Related research profiles
Adalank Spray
Molecular identity needs further verification
Source verification pending
0 selected publications · 0 human intervention studies
Adamax
Molecular identity needs further verification
Source verification pending
0 selected publications · 0 human intervention studies
Adamax 1032 Spray
Molecular identity needs further verification
Source verification pending
0 selected publications · 0 human intervention studies
Cerebrolysin
Molecular identity needs further verification
7 selected publications · 5 human intervention studies · 40 registered trials
Dihexa
C27H44N4O5
504.7 g/mol · PubChem CID 129010512
2 selected publications · 0 human intervention studies
Fasoracetam Powder
C10H16N2O2
196.25 g/mol · PubChem CID 198695
3 selected publications · 1 human intervention study · 6 registered trials
Small molecule · highest stage: Phase 2